Company intelligence / Profile preview

Resproly

Zhuhai, Guangdong, Chinaen.resproly.com ↗

Ownership: Private
Employees: ~200
Development stage: Preclinical

Overview

Resproly has developed a pipeline of inhaled therapies for respiratory and CNS diseases. Its lead proprietary candidate RSN0402 is in Phase 1 clinical trials for idiopathic pulmonary fibrosis. The company also develops generic versions of established inhaled drugs and has experience with complex generics approved in major markets[3][4].

Therapeutic areas: PulmonologyCardiovascularNeurology
Modalities: Small moleculesInhaled drug formulations (MDI, DPI, nebulizers, nasal sprays)
Industry: Biotech

Drug pipeline

1 asset

RSN0402

Partnerships

No specific major pharma partnerships disclosed; investors include CAS Investment Management, YuanBio Venture Capital, Cowin Capital, Qianhai FOF, Tianfeng Capital, Efung Capital[2].

Beyond the preview

Go deeper on Resproly.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Resproly.

Explore the full profile